Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia

The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogenesis

(2010) Alberto M. Martelli et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

I B kinase overcomes PI3K/Akt and ERK/MAPK to control FOXO3a activity in acute myeloid leukemia

(2010) N. Chapuis et al.   BLOOD

Targeting the translational machinery as a novel treatment strategy for hematologic malignancies

(2010) P. R. Hagner et al.   BLOOD

Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor

(2010) B. Hoang et al.   BLOOD

Chemotherapy resistance in acute lymphoblastic leukemia requires hERG1 channels and is overcome by hERG1 blockers

(2010) S. Pillozzi et al.   BLOOD

Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in development

(2010) Alisa B. Lee-Sherick et al.   BRITISH JOURNAL OF HAEMATOLOGY

T-Lymphoblastic Lymphoma Cells Express High Levels of BCL2, S1P1, and ICAM1, Leading to a Blockade of Tumor Cell Intravasation

(2010) Hui Feng et al.   CANCER CELL

Genetic Dissection of the Oncogenic mTOR Pathway Reveals Druggable Addiction to Translational Control via 4EBP-eIF4E

(2010) Andrew C. Hsieh et al.   CANCER CELL

Activity of the Novel Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 against T-Cell Acute Lymphoblastic Leukemia

(2010) F. Chiarini et al.   CANCER RESEARCH

mTOR Activation Induces Tumor Suppressors that Inhibit Leukemogenesis and Deplete Hematopoietic Stem Cells after Pten Deletion

(2010) Jae Y. Lee et al.   Cell Stem Cell

Erucylphosphohomocholine, the first intravenously applicable alkylphosphocholine, is cytotoxic to acute myelogenous leukemia cells through JNK- and PP2A-dependent mechanisms

(2010) A M Martelli et al.   LEUKEMIA

Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies

(2010) N Chapuis et al.   LEUKEMIA

The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL patients treated on the ALL–BFM 2000 protocol can be separated from FBXW7 loss of function

(2010) C Kox et al.   LEUKEMIA

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor

(2010) Matthew R Janes et al.   NATURE MEDICINE

Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy

(2010) C A Sparks et al.   ONCOGENE

Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil™) and potential of other CXCR4 antagonists as stem cell mobilizers

(2010) Erik De Clercq   PHARMACOLOGY & THERAPEUTICS

Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells

(2010) Nathalie Carayol et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Interconnecting molecular pathways in the pathogenesis and drug sensitivity of T-cell acute lymphoblastic leukemia

(2009) T. Sanda et al.   BLOOD

A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma

(2009) Y.-W. Lin et al.   BLOOD

Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia

(2009) J. Tamburini et al.   BLOOD

Dual Inhibition of Class IA Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin as a New Therapeutic Option for T-Cell Acute Lymphoblastic Leukemia

(2009) F. Chiarini et al.   CANCER RESEARCH

Therapeutic targeting of microenvironmental interactions in leukemia: Mechanisms and approaches

(2009) Marina Konopleva et al.   DRUG RESISTANCE UPDATES

mTOR signaling at a glance

(2009) M. Laplante et al.   JOURNAL OF CELL SCIENCE

Targeted therapy in T-cell malignancies: dysregulation of the cellular signaling pathways

(2009) W-L Zhao   LEUKEMIA

The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group

(2009) A Larson Gedman et al.   LEUKEMIA

Negative prognostic impact of PTEN mutation in pediatric T-cell acute lymphoblastic leukemia

(2009) P Y Jotta et al.   LEUKEMIA

Novel benzylidene-thiazolidine-2,4-diones inhibit Pim protein kinase activity and induce cell cycle arrest in leukemia and prostate cancer cells

(2009) Z. Beharry et al.   MOLECULAR CANCER THERAPEUTICS

Pim-1 plays a pivotal role in hypoxia-induced chemoresistance

(2009) J Chen et al.   ONCOGENE

Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2

(2009) Morris E Feldman et al.   PLOS BIOLOGY

Bcl-2 inhibitors: small molecules with a big impact on cancer therapy

(2008) M Vogler et al.   CELL DEATH AND DIFFERENTIATION

The Bone Marrow Microenvironment as a Tumor Sanctuary and Contributor to Drug Resistance

(2008) M. B. Meads et al.   CLINICAL CANCER RESEARCH

Isolation of Hyperactive Mutants of Mammalian Target of Rapamycin

(2008) Yoichiro Ohne et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability

(2008) Ana Silva et al.   JOURNAL OF CLINICAL INVESTIGATION

The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism

(2008) F Chiarini et al.   LEUKEMIA

Interleukin-4 stimulates proliferation and growth of T-cell acute lymphoblastic leukemia cells by activating mTOR signaling

(2008) B A Cardoso et al.   LEUKEMIA

Targeting the leukemic stem cell: the Holy Grail of leukemia therapy

(2008) N Misaghian et al.   LEUKEMIA

CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers

(2008) J A Burger et al.   LEUKEMIA

Multi-genetic events collaboratively contribute to Pten-null leukaemia stem-cell formation

(2008) Wei Guo et al.   NATURE